{'fraction_non_alphanumeric': 0.028771384136858476, 'fraction_numerical': 0.027216174183514776, 'mean_word_length': 4.771300448430493, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Serum and urinary zinc in fulminant hepatic failure

Patients with chronic hepatic encephalopathy have been shown to have low serum zinc levels. Moreover, in a controlled study, significant improvement was seen in these patients on oral zinc supplementation. Information on zinc status in fulminant hepatic failure is insufficient. Serum and urinary zinc abnormalities were studied in 22 patients with fulminant hepatic failure (FHF) and they were compared with age‐ and sex‐matched controls. The mean serum zinc values were significantly less in patients with FHF (72.7 ± 3.7 μg/100 mL versus 107.9 ± 6.2 μg/100 mL) while the urinary zinc values were significantly higher compared with controls (603.5 ± 9.3 μg/24 h versus 334.4 ± 10 μg/24 h). The serum zinc levels significantly and progressively decreased, while urinary zinc significantly increased after admission in patients with FHF. The serum zinc values in the group that survived were significantly higher than those in the group of patients who died. Correspondingly, urinary zinc was lower in survivors than in the group that expired. This study indicates that serum and urinary zinc levels could be used as a prognostic indicator in FHF. A therapeutic trial with zinc supplementation is justified in this group of patients.